JPWO2020191163A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020191163A5 JPWO2020191163A5 JP2021556509A JP2021556509A JPWO2020191163A5 JP WO2020191163 A5 JPWO2020191163 A5 JP WO2020191163A5 JP 2021556509 A JP2021556509 A JP 2021556509A JP 2021556509 A JP2021556509 A JP 2021556509A JP WO2020191163 A5 JPWO2020191163 A5 JP WO2020191163A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- positions
- nucleotide sequence
- scap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820895P | 2019-03-20 | 2019-03-20 | |
| US62/820,895 | 2019-03-20 | ||
| PCT/US2020/023564 WO2020191163A1 (en) | 2019-03-20 | 2020-03-19 | Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525546A JP2022525546A (ja) | 2022-05-17 |
| JPWO2020191163A5 true JPWO2020191163A5 (https=) | 2023-03-20 |
| JP2022525546A5 JP2022525546A5 (https=) | 2023-03-20 |
Family
ID=70285941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556509A Pending JP2022525546A (ja) | 2019-03-20 | 2020-03-19 | ステロール調節エレメント結合転写タンパク質切断活性化タンパク質（ｓｃａｐ）阻害剤による上昇した脂質レベルの治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11331332B2 (https=) |
| EP (1) | EP3942047A1 (https=) |
| JP (1) | JP2022525546A (https=) |
| CN (1) | CN113825839A (https=) |
| CA (1) | CA3133002A1 (https=) |
| WO (1) | WO2020191163A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117757790A (zh) * | 2022-11-17 | 2024-03-26 | 北京福元医药股份有限公司 | 抑制SCAP基因表达的siRNA、其缀合物和药物组合物及用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| US5631356A (en) | 1992-04-03 | 1997-05-20 | Gist-Brocades, N.V. | Selective N-acylation of amino alcohols |
| LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| FR2710337B1 (fr) | 1993-09-23 | 1995-12-08 | Gerard Coquerel | Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé. |
| US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| HRP20030498A2 (en) | 2000-12-21 | 2005-04-30 | Aventis Pharma Deutschland Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| US20080249040A1 (en) | 2001-05-18 | 2008-10-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of sterol regulatory element binding protein 1 (SREBP1) gene expression using short interfering nucleic acid (siNA) |
| US20050014177A1 (en) | 2003-05-19 | 2005-01-20 | Koustubh Ranade | Human sterol response element binding protein 1 (SREBP1) single nucleotide polymorphisms |
| AU2007297388A1 (en) * | 2006-09-18 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of scap and therapeutic uses thereof |
| JP2018507234A (ja) * | 2015-03-04 | 2018-03-15 | メディベイション テクノロジーズ エルエルシー | 肝臓線維症、コレステロールの上昇およびインスリン抵抗性を処置する際における使用のためのｓｒｅｂｐ遮断薬 |
| WO2017100542A1 (en) | 2015-12-10 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof |
| WO2019141723A1 (en) | 2018-01-18 | 2019-07-25 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting srebp1 |
-
2020
- 2020-03-19 WO PCT/US2020/023564 patent/WO2020191163A1/en not_active Ceased
- 2020-03-19 CA CA3133002A patent/CA3133002A1/en active Pending
- 2020-03-19 CN CN202080036542.8A patent/CN113825839A/zh active Pending
- 2020-03-19 JP JP2021556509A patent/JP2022525546A/ja active Pending
- 2020-03-19 EP EP20719003.4A patent/EP3942047A1/en active Pending
- 2020-03-19 US US16/823,832 patent/US11331332B2/en active Active
-
2022
- 2022-04-13 US US17/719,588 patent/US20220323483A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3202914B2 (en) | Method for treating a neurodegenerative disease | |
| CA2731643C (en) | Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases | |
| JP2006517092A (ja) | 心不全遺伝子の決定及び治療薬スクリーニング | |
| WO2008064519A1 (en) | Methods and compositions for diagnosis of esophageal cancer and prognosis and improvement of patient survival | |
| US12331362B2 (en) | Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof | |
| US10364470B2 (en) | Long non-coding RNA expressed in aggressive cancer | |
| CN101501194A (zh) | 老年性黄斑变性的预防和治疗 | |
| JP2008512984A5 (https=) | ||
| US20200147118A1 (en) | Compositions and methods for detection, risk assessment and treatment of diabetes, obesity, and inflammation | |
| JPWO2020191163A5 (https=) | ||
| JPWO2020154268A5 (https=) | ||
| JPWO2020191141A5 (https=) | ||
| JP2007511474A5 (https=) | ||
| CN102399870B (zh) | 一种确定食道癌病人生存预后的试剂 | |
| JP2008506354A (ja) | 高脂血症、異常脂質血症、および不完全な炭水化物代謝と関連するｓｎｐの同定 | |
| CN118541481A (zh) | 用分化簇109(cd109)抑制剂治疗骨矿物质密度降低的方法 | |
| CN118234513A (zh) | 使用钠电压门控通道α亚基11(SCN11A)抑制剂治疗头痛和偏头痛的方法 | |
| Tjärnlund-Wolf et al. | Allelic imbalance of tissue-type plasminogen activator (t-PA) gene expression in human brain tissue | |
| CN119587570B (zh) | 一种igf-1r基因表达抑制剂在制备延缓衰老和改善老年疾病的药物中的应用 | |
| JPWO2021262601A5 (https=) | ||
| JP2019216658A (ja) | 侵襲性歯周炎の存在またはリスクを判定する方法 | |
| JPWO2020139830A5 (https=) | ||
| WO2023141577A2 (en) | Methods of improving health with apolipoprotein e (apoe) inhibitors | |
| JP2024524374A (ja) | 溶質輸送体ファミリー９アイソフォームａ３調節因子２（ｓｌｃ９ａ３ｒ２）阻害剤による高血圧症の治療 | |
| JP2024545873A (ja) | インテグリンサブユニットα１（ＩＴＧＡ１）阻害剤による肺の状態の治療 |